Article
Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Dec 2005
Yauch Robert L, Januario Thomas, Eberhard David A, Cavet Guy, Zhu Wenjing, Fu Ling, Pham Thinh Q, Soriano Robert, Stinson Jeremy, Seshagiri Somasekar, Modrusan Zora, Lin Chin-Yu, O'Neill Vincent, Amler Lukas C
Abstract excerpt
Significant improvements in the outcome of non-small cell lung carcinoma (NSCLC) have been reported in patients treated with the epidermal growth factor receptor (EGFR) inhibitor, erlotinib. To discover biomarkers for the enrichment of patients who might benefit from treatment, a pharmacogenomic approach was used to identify gene signatures that may predict erlotinib activity using in vitro model systems....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
